Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ICCM

Icecure Medical Ltd

Dec 12 • 04:00PM ET

0.9400

Dollar change +0.1050
Percentage change 12.57	%

Healthcare • Medical Devices • Israel • NASD

Peers: BMRN NBIX ANIK BLFS CRIS OSUR QURE TGTX VRTX XBIT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.29	Insider Own	55.46%	Shs Outstand	54.78M	Perf Week	13.39%
Market Cap	51.49M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.00%	Shs Float	22.06M	Perf Month	59.30%
Income	-13.83M	PEG	-	EPS next Q	-0.07	Inst Own	0.39%	Short Float	6.66%	Perf Quarter	51.61%
Sales	3.67M	P/S	14.03	EPS this Y	11.46%	Inst Trans	-43.12%	Short Ratio	2.11	Perf Half Y	23.68%
Book/sh	0.18	P/B	5.12	EPS next Y	14.12%	ROA	-79.74%	Short Interest	1.47M	Perf Year	-1.44%
Cash/sh	0.19	P/C	4.83	EPS next 5Y	-	ROE	-111.35%	52W Range	0.48 - 1.57	Perf YTD	-12.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-0.26%	ROI	-134.55%	52W High	-40.13%	Beta	-
Dividend TTM	-	Quick Ratio	2.27	Sales past 5Y	33.95%	Gross Margin	43.67%	52W Low	95.83%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	2.67	EPS Y/Y TTM	37.65%	Oper. Margin	-397.33%	RSI (14)	73.98	Volatility	7.36% 9.61%
Employees	77	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-376.85%	Recom	1.00	Target Price	3.37
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	8.10%	Payout	-	Rel Volume	1.18	Prev Close	0.83
Sales Surprise	-6.56%	EPS Surprise	-6.67%	Sales Q/Q	102.45%	Earnings	Nov 26 BMO	Avg Volume	696.47K	Price	0.94
SMA20	24.92%	SMA50	36.92%	SMA200	9.62%	Trades		Volume	823,848	Change	12.57%

Dec-05-24 08:30AM	IceCure's ProSense Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results (PR Newswire)
Nov-26-24 09:40AM	IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:30AM	IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense Cryoablation (PR Newswire)
Nov-25-24 08:30AM	IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office (PR Newswire) +9.13%
Nov-20-24 08:30AM	IceCure Medical to Report Third Quarter 2024 Financial and Operational Results on November 26, 2024 (PR Newswire)
08:30AM	Loading…
08:30AM	IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 (PR Newswire)
Nov-19-24 08:30AM	IceCure's ProSense Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health (PR Newswire)
Nov-11-24 06:35AM	IceCures cryoablation system for breast cancer treatment gains FDA panel support (Medical Device Network) -6.77%
Nov-08-24 07:00AM	FDA Advisory Panel Votes in Favor of IceCure's ProSense Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer (PR Newswire) -11.73%
Oct-29-24 08:30AM	Upcoming FDA Advisory Panel for IceCure's ProSense Marketing Authorization Receives Large Number of Public Comments from Stakeholders (PR Newswire) +18.18%
Oct-21-24 08:30AM	IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System (PR Newswire) +7.50%
Oct-07-24 08:15AM	IceCure's ProSense Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference (PR Newswire)
Sep-24-24 08:15AM	IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate (PR Newswire)
Sep-16-24 08:00AM	Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues (PR Newswire)
Sep-12-24 08:00AM	IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 (PR Newswire)
08:30AM	Loading…
Sep-04-24 08:30AM	IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences (PR Newswire)
Aug-28-24 08:30AM	USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies (PR Newswire) -5.42%
Aug-20-24 12:52PM	ICCM Stock Earnings: Icecure Medical Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +18.18%
09:40AM	IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:30AM	IceCure Medical Reports 20% Growth in ProSense System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets (PR Newswire)
Aug-14-24 08:30AM	IceCure's ProSense Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery (PR Newswire)
Aug-13-24 08:30AM	IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024 (PR Newswire)
Aug-07-24 08:30AM	IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: 'Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials' (PR Newswire)
Jul-22-24 11:53AM	IceCure presents hat-trick of positive trial data for cryoablation device (Medical Device Network) -6.66%
08:30AM	99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society (PR Newswire)
04:52AM	IceCure Medical receives Nasdaq compliance notice (Medical Device Network)
Jul-19-24 04:30PM	IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
Jul-11-24 01:22PM	IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint (Zacks)
Jul-09-24 08:30AM	European Study Provides More Evidence Supporting IceCure's ProSense is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer (PR Newswire)
Jul-03-24 11:50AM	IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod (Zacks)
05:52AM	Loading…
Jul-02-24 05:52AM	FDA grants marketing authorisation for IceCures XSense Cryoablation System (Medical Device Network)
Jul-01-24 08:30AM	U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes (PR Newswire)
Jun-18-24 08:30AM	IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024 (PR Newswire)
Jun-17-24 07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -6.00%
Jun-12-24 08:30AM	Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function (PR Newswire)
Jun-04-24 12:00PM	IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade (Zacks) -7.62%
08:30AM	FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense, Decision Expected Early 2025; Aligns with Commercial Readiness Plan (PR Newswire)
May-28-24 12:52PM	ICCM Stock Earnings: Icecure Medical Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:30AM	IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024 (PR Newswire)
May-21-24 08:30AM	IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024 (PR Newswire)
May-20-24 08:30AM	IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase (PR Newswire)
May-07-24 08:30AM	Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense, Adding to Continued Positive Data Published Globally (PR Newswire)
Apr-30-24 10:30AM	As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response (PR Newswire)
Apr-18-24 11:07AM	IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA (Zacks)
Apr-15-24 08:35AM	IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer (PR Newswire) +8.00%
Apr-04-24 09:28AM	IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-03-24 12:52PM	ICCM Stock Earnings: Icecure Medical Meets EPS, Beats Revenue for Q4 2023 (InvestorPlace) -6.72%
08:30AM	IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance (PR Newswire)
Apr-02-24 08:30AM	IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes (PR Newswire)
Mar-27-24 08:30AM	IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 (PR Newswire)
Mar-19-24 08:30AM	IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy (PR Newswire)
Mar-12-24 08:30AM	IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes (PR Newswire)
Mar-07-24 08:30AM	IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference (PR Newswire)
Mar-04-24 08:30AM	IceCure's ProSense a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 (PR Newswire)
Feb-27-24 08:00AM	Fourth BRIIT Conference in India Features IceCure's ProSense in Breast Cancer Imaging & Interventions Workshop (PR Newswire)
Feb-26-24 08:00AM	Study Using IceCure's ProSense Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer (PR Newswire)
Feb-15-24 08:00AM	IceCure's ProSense to be Featured at Two Upcoming Medical Conferences in Japan (PR Newswire)
Jan-30-24 08:00AM	U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense for Early-Stage Breast Cancer (PR Newswire) +7.25%
Jan-29-24 08:00AM	IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class (PR Newswire)
Jan-16-24 08:00AM	IceCure Medical's ProSense Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation (PR Newswire)
Jan-12-24 04:05PM	IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule (GlobeNewswire) -7.04%
Jan-10-24 08:00AM	IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results (PR Newswire) +6.82%
Jan-03-24 08:00AM	New Study Reports IceCure's ProSense Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response (PR Newswire) +7.76%
Dec-13-23 08:00AM	Study Using IceCure's ProSense Finds: 'Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients' (PR Newswire)
Nov-29-23 08:00AM	IceCure's ProSense Deepens Regulatory Approval in India (PR Newswire) -17.34%
Nov-28-23 01:41PM	5 Investors Betting Big on IceCure Medical (ICCM) Stock (InvestorPlace) +83.11%
08:00AM	IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate (PR Newswire)
Nov-15-23 09:15AM	IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:00AM	IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights (PR Newswire)
07:30AM	IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer (PR Newswire)
Nov-08-23 08:00AM	IceCure Medical to Report Third Quarter 2023 Financial & Operational Results on November 15, 2023 (PR Newswire)
Nov-06-23 08:00AM	Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's ProSense Cryoablation System (PR Newswire)
Nov-03-23 04:00PM	IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
Oct-30-23 08:00AM	IceCure's ICE3 Trial Results Demonstrating 96.91% Recurrence Free Rate Featured in a Presentation at BISICON 2023 in India (PR Newswire) -5.47%
Oct-25-23 08:00AM	Independent Scientific Paper by Doctors Using IceCure's ProSense Published in Journal of Breast Imaging Presents Advantages of Cryoablation Breast Conserving Over Surgery in Early Breast Cancer Patients (PR Newswire) -5.86%
Oct-05-23 08:00AM	Women Deemed Inoperable for Breast Cancer Benefitted from IceCure Medical's ProSense as an Independent Study Performed in Italy Showed a Tumor Reduction Rate of 93.43% to 96.81% (PR Newswire) +7.22%
Oct-02-23 08:00AM	Independent Study Validates IceCure's ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Success Rate (PR Newswire) +58.29%
Sep-22-23 08:00AM	Renowned Spanish Radiologist Lucía Graña-López to Present Data Using IceCure Medical's ProSense at European Society of Breast Imaging Scientific Meeting 2023 (PR Newswire) -7.53%
Sep-20-23 07:00AM	IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer (PR Newswire) -36.11%
Sep-08-23 08:00AM	IceCure Medical to Join Hands-On Cryoablation Session with ProSense and Host Symposium Led by Renowned Doctors at the CIRCE 2023 Annual Congress (PR Newswire)
Sep-05-23 08:00AM	IceCure Medical's ProSense Cryoablation System Receives Regulatory Approval in Brazil (PR Newswire)
Aug-28-23 08:00AM	IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America (PR Newswire)
Aug-21-23 08:00AM	IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium (PR Newswire)
Aug-14-23 08:00AM	IceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum (PR Newswire)
Aug-07-23 08:00AM	IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023 (PR Newswire) -9.57%
Jul-27-23 06:30AM	IceCure Medical's (NASDAQ:ICCM) investors will be pleased with their enviable 577% return over the last three years (Simply Wall St.)
Jul-24-23 08:00AM	Health Canada Approves IceCure Medical's Minimally Invasive ProSense Cryoablation System (PR Newswire)
Jul-17-23 08:00AM	IceCure Medical Expands Distribution of ProSense® into Portugal Through Agreement with Medicinália Cormédica: Upfront Systems & Probes Sales (PR Newswire) -6.82%
Jun-13-23 08:00AM	IceCure Medical to Review Recent Progress at Maxim Group's Virtual Healthcare Conference (PR Newswire)
May-31-23 08:00AM	IceCure's ProSense Installation in India is the First to Offer Cryoablation for the Treatment of Breast Cancer in the Country (PR Newswire)
May-22-23 08:00AM	IceCure Medical Reports First Quarter 2023 Financial & Operational Results (PR Newswire)
May-15-23 08:00AM	IceCure to Report First Quarter 2023 Financial & Operational Results on May 22, 2023 (PR Newswire)
May-01-23 08:00AM	Cryoablation Takes Center Stage at American Society of Breast Surgeons' 24th Annual Meeting (PR Newswire) -7.04%
Apr-24-23 08:00AM	IceCure Medical to Provide Educational Support in a First-of-its-Kind Cryotherapy Course at the American Society of Breast Surgeons' 24th Annual Meeting (PR Newswire)
Apr-20-23 08:00AM	IceCure's ProSense System Used in Endometriosis Cryoablation Study That Demonstrated Efficacy Rate of 92.8% to Avoid Secondary Surgery (PR Newswire) +11.07%
Apr-19-23 08:00AM	IceCure Medical Ordinary Shares to Trade Exclusively on Nasdaq: Company to Voluntarily Delist Shares from Trading on the Tel Aviv Stock Exchange (PR Newswire)
Mar-29-23 08:00AM	IceCure Medical Reports 2022 Full Year Financial Results & Recent Corporate Developments; Milestone Achievements Expected to Drive Revenue Growth in 2023 (PR Newswire) -8.59%
Mar-28-23 08:00AM	IceCure Medical Receives Regulatory Approval in China for Commercial Use of its IceSense3 Disposable Cryoprobes (PR Newswire) +14.29%
Mar-20-23 08:00AM	IceCure Medical to Report 2022 Full Year Financial & Operational Results on March 29, 2023 (PR Newswire)
Mar-09-23 04:09PM	7 Speculative Penny Stocks to Bet On This March (InvestorPlace)

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ICCM

Icecure Medical Ltd

Upgrade your FINVIZ experience